YMAB
Income statement / Annual
Last year (2024), Y-mAbs Therapeutics, Inc.'s total revenue was $87.69 M,
an increase of 3.38% from the previous year.
In 2024, Y-mAbs Therapeutics, Inc.'s net income was -$29.67 M.
See Y-mAbs Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$87.69 M |
$84.82 M |
$65.27 M |
$34.90 M |
$20.75 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$15.25 M
|
$11.42 M
|
$7.57 M
|
$2.51 M
|
$2.20 M
|
$166.00 K
|
$29.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
$72.43 M
|
$73.40 M
|
$57.70 M
|
$32.38 M
|
$18.55 M
|
-$166.00 K
|
-$29.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.83
|
0.87
|
0.88
|
0.93
|
0.89
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$48.99 M
|
$54.22 M
|
$91.57 M
|
$93.25 M
|
$93.70 M
|
$63.49 M
|
$34.27 M
|
$14.31 M
|
$13.86 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$44.79 M
|
$19.51 M
|
$8.96 M
|
$4.94 M
|
$3.18 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$54.65 M
|
$44.86 M
|
$60.94 M
|
$54.57 M
|
$44.79 M
|
$19.51 M
|
$8.96 M
|
$4.94 M
|
$3.18 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$44.00 K
|
$83.00 K
|
-$18.00 K
|
| Operating Expenses |
$103.64 M
|
$99.08 M
|
$152.51 M
|
$147.82 M
|
$138.48 M
|
$83.00 M
|
$43.23 M
|
$19.24 M
|
$17.04 M
|
| Cost And Expenses |
$118.89 M
|
$110.49 M
|
$160.08 M
|
$150.33 M
|
$140.69 M
|
$83.00 M
|
$43.23 M
|
$19.24 M
|
$17.04 M
|
| Interest Income |
$1.39 M
|
$4.81 M
|
$0.00
|
$0.00
|
$598.00 K
|
$1.98 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$757.00 K
|
$1.85 M
|
$0.00
|
$1.98 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$535.00 K
|
$735.00 K
|
$839.00 K
|
$782.00 K
|
$396.00 K
|
$166.00 K
|
$29.00 K
|
$19.24 M
|
$17.04 M
|
| EBITDA |
-$30.67 M |
-$24.94 M |
-$94.73 M |
-$54.49 M |
-$119.54 M |
-$82.84 M |
-$43.20 M |
$83.00 K |
-$18.00 K |
| EBITDA Ratio |
-0.35
|
-0.29
|
-1.45
|
-1.56
|
-5.76
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.36
|
-0.3
|
-1.45
|
-3.31
|
-5.78
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.39 M
|
$4.81 M
|
-$757.00 K
|
$60.16 M
|
$598.00 K
|
$1.98 M
|
-$44.00 K
|
$83.00 K
|
-$18.00 K
|
| Income Before Tax |
-$29.81 M
|
-$20.87 M
|
-$95.57 M
|
-$55.28 M
|
-$119.34 M
|
-$81.03 M
|
-$43.27 M
|
-$19.16 M
|
-$17.06 M
|
| Income Before Tax Ratio |
-0.34
|
-0.25
|
-1.46
|
-1.58
|
-5.75
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$146.00 K
|
$561.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$44.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$29.67 M
|
-$21.43 M
|
-$95.57 M
|
-$55.28 M
|
-$119.34 M
|
-$78.89 M
|
-$43.27 M
|
-$19.16 M
|
-$17.06 M
|
| Net Income Ratio |
-0.34
|
-0.25
|
-1.46
|
-1.58
|
-5.75
|
0
|
0
|
0
|
0
|
| EPS |
-0.67 |
-0.49 |
-2.2 |
-1.28 |
-2.97 |
-2.24 |
-1.5 |
-0.58 |
-0.97 |
| EPS Diluted |
-0.67 |
-0.49 |
-2.2 |
-1.28 |
-2.97 |
-2.24 |
-1.5 |
-0.58 |
-0.97 |
| Weighted Average Shares Out |
$44.33 M
|
$43.65 M
|
$43.70 M
|
$43.18 M
|
$40.12 M
|
$35.18 M
|
$28.77 M
|
$33.29 M
|
$17.64 M
|
| Weighted Average Shares Out Diluted |
$44.33 M
|
$43.65 M
|
$43.70 M
|
$43.18 M
|
$40.12 M
|
$35.18 M
|
$28.77 M
|
$33.29 M
|
$17.64 M
|
| Link |
|
|
|
|
|
|
|
|
|
